PMD Device Solutions AB

Equities

PMDS

SE0021513645

Biotechnology & Medical Research

Delayed Nasdaq Stockholm Other stock markets 10:11:20 2024-04-29 am EDT			5-day change	1st Jan Change
7.15 ^SEK	-5.30%		-12.80%	-33.12%

Apr. 11	PMD Device Solutions AB (OM:PMDS) acquired Coala Life Inc from Coala-Life Group AB for SEK 3.6 million.	CI
Apr. 09	PMD Device Solutions to Purchase Coala-Life Group's US Unit	MT

Redeye Initiates Coverage of PMD Device Solutions

March 04, 2024 at 03:02 am EST

Redeye initiates coverage of PMD Device Solutions, an Ireland-based company listed on the NASDAQ First North Growth Market following a reverse acquisition by Promore Pharma AB in December 2023. Its product “RespiraSense” was developed between 2011 and 2021, securing European approval in 2015 and US FDA approval in 2022. We expect strong growth in the upcoming 3-year period. The main catalysts for the stock are an extended English launch, higher virtual ward (hubs) contribution, and early 2025 contributions from Germany and the US.

Read more and download the Research Report.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Latest news about PMD Device Solutions AB

PMD Device Solutions AB (OM:PMDS) acquired Coala Life Inc from Coala-Life Group AB for SEK 3.6 million.	Apr. 10	CI
PMD Device Solutions to Purchase Coala-Life Group's US Unit	Apr. 09	MT
PMD Device Solutions AB (OM:PMDS) intends to acquire Coala Life Inc. from Coala-Life Group AB.	Apr. 08	CI
PMD Device Solutions AB Begins Preparation for First German Hospital Pilot	Mar. 25	CI
PMD Device Solutions to Complete Reverse Stock Split; Shares Soar	Jan. 29	MT
Promore Pharma AB will Change its Ticker to PMDS from PROMO	Jan. 17	CI
Promore Pharma AB will Change its Name to PMD Device Solutions AB	Jan. 17	CI
Promore Pharma AB Announces Board Appointments	Dec. 29	CI
Pmd Device Solutions AB completed the acquisition of Promore Pharma AB (OM:PROMO) in a reverse merger transaction.	Dec. 28	CI
Transcript : Promore Pharma AB - Special Call	Dec. 18
Promore Pharma to Buy PMD Device Solutions via Reverse Acquisition; Stock Skyrockets	Nov. 29	MT
Pmd Device Solutions AB intends to acquire Promore Pharma AB (OM:PROMO) in a reverse merger transaction for approximately SEK 130 million.	Nov. 28	CI
Promore Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 28	CI
Promore Pharma Enters Voluntary Liquidation	23-10-12	MT
Promore Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-30	CI
Promore Pharma AB Announces CFO Change	23-06-22	CI
Promore Pharma AB Announces CEO Change	23-06-22	CI
Promore Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-23	CI
Promore Pharma AB Auditor Raises 'Going Concern' Doubt	23-05-08	CI
Transcript : Promore Pharma AB - Special Call	23-04-21
Promore Pharma Reports Outcome from Clinical Phase II Study with Ensereptide	23-04-20	CI
Promore Pharma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-02-28	CI
Promore Pharma Reaches the Clean File Milestone in its Phase II Clinical Trial with Ensereptide	23-02-27	CI
Promore Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-29	CI
Promore Pharma AB Announces Composition of Nomination Committee	22-11-23	CI

Chart PMD Device Solutions AB

Duration

Period

More charts

Company Profile

PMD Device Solutions AB is a Sweden-based biopharmaceutical company. The Company deals with research, development and production of medical technical products and equipment and related activities. It specializes in the development of therapeutic peptides for the bioactive wound care market. The Company possesses two therapeutic peptides, PXL01 and LL-37, in late stage clinical phase. The peptides are derived from human sequences that are part of innate immune system, having multiple biological functions and properties. PXL01 aims to prevent post-surgical adhesions and scars and is for clinical phase III-studies on patients performing tendon repair surgery in the hand. LL-37 aims to heal chronic wounds and is in a clinical phase IIb study on patients with venous leg ulcers and in a clinical phase IIa study on patients with diabetic foot ulcers. PMD Device Solutions AB develops and sells medical products for respiratory monitoring.

Sector

Biotechnology & Medical Research

Calendar

2024-05-27 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
PMD DEVICE SOLUTIONS AB	-33.12%	14.36M
VERTEX PHARMACEUTICALS INCORPORATED	-2.53%	103B
REGENERON PHARMACEUTICALS, INC.	+1.77%	95.28B
ARGENX SE	+1.60%	22.15B
BIONTECH SE	-15.39%	21.02B
GENMAB A/S	-8.58%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-13.23%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.98%	13.68B
SAREPTA THERAPEUTICS, INC.	+34.71%	12.17B

Bio Therapeutic Drugs